Evidence map›Paper›PMID 36604127›Full record

ArticleBMJ open2023

Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity.

Noemie Lang, Antonella Diciola, Intidhar Labidi-Galy, Frédéric Ris, Mariagrazia Di Marco, Nicolas Mach, Patrick Petignat, Christian Toso, Manuela Undurraga, Martin Hubner

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04000906 (A Phase Ib Trial of Intraperitoneal Cisplatin and Nab-paclitaxel Administered by Pressurized Intraperitoneal Aerosol Chemotherapy), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04000906 phase1unknown statusnot on this map

A Phase Ib Trial of Intraperitoneal Cisplatin and Nab-paclitaxel Administered by Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Advanced Malignancies Confined to the Peritoneal Cavity

TypeinterventionalSponsorUniversity Hospital, GenevaRan2020 to 2024Enrolled18ConditionsPeritoneal CarcinomatosisArmsNab paclitaxel, Cisplatin
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. PIPAC for Gastrointestinal Malignancies.Journal of clinical medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Noemie LangService d'oncologie, Département d'Oncologie, Hôpitaux Universitaires de Genève, Genève, Switzerland noemie.lang@hcuge.ch.ORCID 0000-0003-1243-4888
Antonella DiciolaService d'oncologie, Département d'Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Intidhar Labidi-GalyService d'oncologie, Département d'Oncologie, Hôpitaux Universitaires de Genève, Genève, Switzerland.
Frédéric RisDépartement de Chirurgie, Hôpitaux Universitaires Genève, Genève, Switzerland.
Mariagrazia Di MarcoService d'oncologie, Département d'Oncologie, Hôpitaux Universitaires de Genève, Genève, Switzerland.
Nicolas MachService d'oncologie, Département d'Oncologie, Hôpitaux Universitaires de Genève, Genève, Switzerland.
Patrick PetignatDépartement Gynécologie et Obstétrique, Hôpitaux Universitaires Genève, Genève, Switzerland.
Christian TosoDépartement de Chirurgie, Hôpitaux Universitaires Genève, Genève, Switzerland.
Manuela UndurragaDépartement Gynécologie et Obstétrique, Hôpitaux Universitaires Genève, Genève, Switzerland.
Martin HubnerDépartement de chirurgie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Hôpital Beau-Séjour · CHUniversity Hospital of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIntraperitoneal dissemination is a major problem resulting in very poor prognosis and a rapid marked deterioration in the quality of life of patients. Pressurised intraperitoneal aerosol chemotherapy (PIPAC) is an emergent laparoscopic procedure aiming to maximise local efficacy and to reduce systemic side effects. METHODS AND ANALYSIS: Nab-PIPAC, a bicentre open-label phase IB, aims to evaluate safety of nab-paclitaxel and cisplatin association using in patients with peritoneal carcinomatosis (PC) of gastric, pancreatic or ovarian origin as ≥1 prior line of systemic therapy. Using a 3+3 design, sequential intraperitoneal laparoscopic application of nab-paclitaxel (7.5, 15, 25, 37.5, 52.5 and 70 mg/m ETHIC AND DISSEMINATION: Ethical approval was obtained from the ethical committees of Geneva and Vaud (CCER-2018-01327). The study findings will be published in an open-access, peer-reviewed journal and presented at relevant conferences and research meetings. TRIAL REGISTRATION NUMBER: NCT04000906.

Indexed as

CisplatinPeritoneal NeoplasmsAerosolsAlbuminsAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase I as TopicDoxorubicinHumansPaclitaxelPeritoneal CavityQuality of Life130-nm albumin-bound paclitaxelAerosolsAlbuminsCisplatinDoxorubicinPaclitaxelAdult oncologyGastrointestinal tumoursGynaecological oncology

Identifiers

PMID36604127
PMCPMC9827272
OpenAlexW4313557566

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.